Company Description
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.
It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds.
The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
| Country | United States |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Peter Ludlum |
Contact Details
Address: 945 Concord Street, Suite 1217 Framingham, Massachusetts 01701 United States | |
| Phone | (888) 355-4440 |
| Website | pulmatrix.com |
Stock Details
| Ticker Symbol | PULM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574235 |
| CUSIP Number | 74584P301 |
| ISIN Number | US74584P3010 |
| Employer ID | 46-1821392 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Peter Ludlum CMA, MBA | Interim Chief Executive Officer and Interim Chief Financial Officer |
| Dr. Alexander M. Klibanov Ph.D. | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 6, 2025 | 10-Q | Quarterly Report |
| Aug 6, 2025 | 8-K | Current Report |
| Jun 16, 2025 | 425 | Filing |
| Jun 16, 2025 | 8-K | Current Report |
| May 15, 2025 | 10-Q | Quarterly Report |
| May 15, 2025 | 8-K | Current Report |
| May 9, 2025 | EFFECT | Notice of Effectiveness |
| May 9, 2025 | 424B3 | Prospectus |
| May 7, 2025 | S-4/A | Filing |
| Apr 17, 2025 | S-4/A | Filing |